Physician profile
Aldo Ribeiros
NPI 1528519881
$3,823.29
in general payments reported to CMS, 2019-2025
25 companies · $928 in 2025
The $928 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.94 · 2020: $168 · 2021: $246 · 2022: $230 · 2023: $868 · 2024: $1,294 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $740.85 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $550.42 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $439.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $436.77 | 2019-2025 | |
| Lilly USA, LLC | $369.51 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $327.83 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $180.77 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $114.05 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $91.03 | 2023-2025 | Eliquis |
| Averitas Pharma INC. | $90.75 | 2023-2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $62.31 | 2020-2023 | |
| Phadia US INC. | $59.99 | 2022-2024 | Immunocap |
| Boston Scientific Corporation | $59.97 | 2025 | Watchman Flx |
| Abbott Laboratories | $42.43 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $39.48 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $28.28 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $28.25 | 2023 | |
| Dynavax Technologies Corporation | $27.22 | 2025 | Heplisav-B |
| Shield Therapeutics INC | $26.19 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.06 | 2025 | Jardiance |
| Medtronic, INC. | $19.62 | 2021 | |
| Eisai INC. | $18.67 | 2021 | |
| Abbvie INC. | $17.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.83 | 2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $13.31 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aldo Ribeiros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.